July 1 | 2022

Dr. Raphael Gruber joins 2cureX as new Medical Director

Read more
June 28 | 2022

2cureX expands distribution of IndiTreat® to Israel

Read more
June 7 | 2022

2cureX AB announces share purchase by the company’s Chairman of the Board of Directors and Executive Management

Read more
May 31 | 2022

Strengthening the IndiTreat® distribution in North Europe

Read more
May 24 | 2022

2cureX publishes interim report for the first quarter 2022

Read more
May 20 | 2022

We invite you to join the 2cureX Q1 Report webcast and Q&A session at 15:00 on 24 May, 2022

Read more
May 17 | 2022

Three IndiTreat® posters have been accepted at ESMO-GI 2022

Read more
May 12 | 2022

2cureX AB nominates Dr. Michael Schaefer to the Board of Directors

Read more
May 11 | 2022

IGNITE update – Eight hospitals have been enrolled in the program

Read more
May 9 | 2022

2cureX presents IndiTreat® clinical results at the Society for Functional Precision Medicine

Read more
May 6 | 2022

2cureX appoints Sedermera Corporate Finance AB to act as a liquidity provider for the Company´s share

Read more
May 5 | 2022

Redeye research interview with 2cureX CEO, Fernando Andreu

Read more
May 3 | 2022

2cureX publishes the annual report for the fiscal year 2021

Read more
April 22 | 2022

Correction of “Notice of annual general meeting of 2cureX AB (publ)” issued on 21st April 2022

Read more
April 21 | 2022

Notice of annual general meeting of 2cureX AB (publ)

Read more
April 21 | 2022

Manuel Fernández joins 2cureX as Director of Quality Assurance and Regulatory Affairs.

Read more
April 14 | 2022

Chairman of the 2cureX Board exercises all warrants within the framework of the 2018 incentive program

Read more
March 15 | 2022

Mangold Fondkommission AB published an updated Analyst Report on 2cureX

Read more